BioLife Solutions, Inc. (BLFS) P/E Ratio History
Deep ValueTrading at -104.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2002–2021
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, BioLife Solutions, Inc. (BLFS) trades at a price-to-earnings ratio of -104.2x, with a stock price of $26.04 and trailing twelve-month earnings per share of $-0.21.
The current P/E is 152% below its 5-year average of 201.2x. Over the past five years, BLFS's P/E has ranged from a low of 1.3x to a high of 901.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, BLFS trades at a 571% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, BLFS trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BLFS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BLFS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BLFS P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $753M | 10.7Lowest | - | +163% | |
| $7B | 153.5 | - | +287%Best | |
| $4B | 92.5 | 61.97 | +104% | |
| $5B | 32.1 | 3.68Best | -16% | |
| $173B | 26.2 | 12.40 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BLFS Historical P/E Data (2002–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q3 | - | $42.32 | $0.09 | 486.4x | +142% |
| FY2021 Q2 | Jun 30 2021 | $44.51 | $0.05 | 901.0x | +348% |
| FY2020 Q4 | - | $39.89 | $0.25 | 157.7x | -22% |
| FY2020 Q3 | Sep 30 2020 | $28.94 | $0.34 | 84.1x | -58% |
| FY2020 Q2 | - | $16.35 | $0.73 | 22.4x | -89% |
| FY2020 Q1 | - | $9.50 | $1.45 | 6.5x | -97% |
| FY2018 Q4 | Dec 31 2018 | $12.03 | $0.12 | 97.2x | -52% |
| FY2018 Q3 | Sep 30 2018 | $17.50 | $0.04 | 452.2x | +125% |
| FY2003 Q1 | Mar 31 2003 | $1.68 | $1.31 | 1.3x | -99% |
| FY2002 Q4 | - | $1.68 | $1.26 | 1.3x | -99% |
| FY2002 Q3 | Sep 30 2002 | $1.96 | $0.65 | 3.0x | -99% |
Average P/E for displayed period: 201.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BLFS — Frequently Asked Questions
Quick answers to the most common questions about buying BLFS stock.
What is BLFS's P/E ratio?
BioLife Solutions, Inc. (BLFS) trailing twelve-month P/E ratio is -104.2x, based on TTM diluted EPS of $-0.21. The 5-year average P/E is 201.2x and the historical range spans 1.3x to 901.0x.
Is BLFS stock overvalued or undervalued?
BLFS trades at -104.2x P/E, below its 5-year average of 201.2x. At the 0th percentile of its historical range (1.3x–901.0x), the stock is priced at a discount to its own history.
Is BLFS stock expensive?
No, BLFS is not expensive on a historical basis. The current P/E of -104.2x is below the 5-year average of 201.2x and sits at the 0th percentile of its valuation range.
What is BLFS's historical P/E range?
Over the past 5 years, BLFS's P/E ratio has ranged from 1.3x to 901.0x, with a median of 84.1x and an average of 201.2x. The current P/E of -104.2x places the stock at the 0th percentile of this range. Full historical data spans 2002–2021.
How does BLFS's P/E compare to the S&P 500?
BLFS trades at -104.2x P/E versus the S&P 500 median of 24.4x. The 527% discount to the market suggests lower growth expectations or perceived higher risk.
How does BLFS's valuation compare to Healthcare peers?
BioLife Solutions, Inc. P/E of -104.2x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BLFS's PEG ratio?
BLFS PEG ratio is N/A, based on a P/E of -104.2x and EPS growth of 43.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BLFS's earnings yield?
BLFS earnings yield is N/A, the inverse of its -104.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.